EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudie

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study

Dawn C Buse, Lindsay A Videnieks, Karissa Charles, Killian Lozach, Kristina M Fanning, Talia A Guidi, Richard B Lipton iD

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70026 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Dawn C Buse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Patient Acceptance of Health Care, Prescription Drugs. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Headache and Migraine Policy Forum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to report rates of payer blocking of prescribed branded migraine medications in total and by race/ethnicity, income, and education, and to examine the relationship between payer blocking and emergency department and inpatient encounters for migraine‐specific and all‐cause reasons in a large US claims database.

Background

Access to prescribed branded migraine medications can be challenging due to restrictive utilization management protocols and may be related to increased healthcare resource utilization. These barriers may disproportionately affect patients based on sociodemographic factors.

Methods

This observational cohort study analyzed data from an integrated database containing electronic medical records, specialty pharmacy, and in‐office dispensing datasets. Individuals with a migraine diagnosis who experienced payer blocking —defined as denial of prescribed branded migraine medications ≥2 times due to step therapy, prior authorization, or related restrictions—between January 1, 2019, and December 31, 2021, were included. Rates of payer blocking were reported for the total sample and by sociodemographic groups. Emergency department (ED) and inpatient encounter rates for migraine‐specific and all‐cause reasons were compared by payer blocking status. Differences were assessed using χ 2 tests with Bonferroni corrected α ( p < 0.0018). Effect sizes were estimated using Cramer's V .

Results

Among 7.7 million patients with ≥1 migraine‐related prescription claim(s), 370,560 actively treated individuals met inclusion criteria for analysis. One in five (20.6%) experienced payer blocking. There were significant differences in the distribution of race/ethnicity, annual household income, and educational attainment categories across payer blocking status groups ( p < 0.001 for all), with small effect sizes (Cramer's V = 0.014–0.034). Patients with a history of payer blocking had significantly higher rates of ED and inpatient encounters for both all‐cause and migraine‐specific reasons ( p < 0.001 for all), although effect sizes were small. This pattern was consistent within racial/and ethnic groups, with significant differences observed for White patients both for migraine‐related and all‐cause ED and inpatient encounters, and Black/African American and Hispanic/Latino patients for migraine‐related encounters ( p < 0.001 for all).

Conclusion

Payer blocking of branded migraine medications was fairly common, affecting one in five patients and was broadly associated with increased healthcare utilization. These findings suggest that payer blocking may disproportionately impact patients according to race/ethnicity, household income, and educational attainment. Although effect sizes were small, the outcomes may provide useful hypotheses for understanding and addressing healthcare disparities in migraine [Correction added on January 31, 2026 after first online publication: typos errors are removed to ensure accuracy].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPatient Acceptance of Health CarePrescription DrugsHumansFemaleAdultMaleCohort StudiesMiddle AgedEmergency Room VisitsEmergency Service, HospitalUnited StatesDatabases, FactualYoung Adult

Stichwörter der Autor:innen

emergency departmenthealth disparitiesinpatient staypayer blockingrace/ethnicitystep‐therapy

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • The Headache and Migraine Policy Forum, Washington, DC, USA.
  • MIST Research, Wilmington, North Carolina, USA.
  • Headache Center, Montefiore Medical Center, Bronx, New York, USA.

ORCID-Profile: Richard B Lipton

Förderung

  • Headache and Migraine Policy Forum

Zitieren

APA

Buse, D. C., Videnieks, L. A., Charles, K., Lozach, K., Fanning, K. M., Guidi, T. A., & Lipton, R. B. (2026). Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70026

Vancouver

Buse DC, Videnieks LA, Charles K, Lozach K, Fanning KM, Guidi TA, et al. Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70026

BibTeX
@article{Buse2026,
  author = {Buse, Dawn C and Videnieks, Lindsay A and Charles, Karissa and Lozach, Killian and Fanning, Kristina M and Guidi, Talia A and Lipton, Richard B},
  title = {Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70026}
}
Kostenlos starten →